

Klebsiella pneumoniae Infections R&D Pipeline Analysis Report, Q4 2020

https://marketpublishers.com/r/K3727CE2D141EN.html

Date: October 2020

Pages: 143

Price: US\$ 2,199.00 (Single User License)

ID: K3727CE2D141EN

Abstracts

Klebsiella pneumoniae Infections Pipeline Overview

The Q4 Klebsiella pneumoniae Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Klebsiella pneumoniae Infections, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.

Klebsiella pneumoniae Infections Disease Types, Symptoms, Causes, and Available Treatment Options

The comprehensive report on the indication presents Klebsiella pneumoniae Infections disease overview, Klebsiella pneumoniae Infections types, Klebsiella pneumoniae Infections symptoms, causes, and FDA/EMA approved treatment options.

Klebsiella pneumoniae Infections Pipeline Trends and Insights

The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Klebsiella pneumoniae Infections indication. The report presents near-term and long-term pipeline development trends and potential insights.

Klebsiella pneumoniae Infections Company Trends and Insights
The report analyzes the development progress, current status, investments,
partnerships, and other developments of 32 companies. Business profiles and contact
details of the companies actively perusing Klebsiella pneumoniae Infections pipeline are
assessed.

Klebsiella pneumoniae Infections R&D Pipeline Development Phase Trends and



Insights

From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Klebsiella pneumoniae Infections discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.

Small Klebsiella pneumoniae Infections companies look for licensing and collaboration partners

High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Klebsiella pneumoniae Infections pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.

Klebsiella pneumoniae Infections Pipeline Market News and Developments during 2020 The Klebsiella pneumoniae Infections industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.

Klebsiella pneumoniae Infections Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and
their progress is included. New mechanisms of actions introduced during the year, route
of administration, orphan drug designation, and others are provided in the study.

New molecular entity details

Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.

Sources and Research Methodology

Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.

Scope and Coverage

Klebsiella pneumoniae Infections pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates



Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.

Company-company partnerships, company-institute partnerships, and investment details of companies are included

32 companies are included including ABAC Therapeutics SA, AEON Medix Inc, Affinivax Inc, Akthelia Pharmaceuticals Ltd, Appili Therapeutics Inc, Armata Pharmaceuticals Inc, BB200 LLC, Bugworks Research India Pvt Ltd, Celdara Medical LLC, ContraFect Corp, Debiopharm International SA, EnBiotix Inc, F. Hoffmann-La Roche Ltd, Fedora Pharmaceuticals Inc, Forge Therapeutics Inc, Kyorin Pharmaceutical Co Ltd, Melinta Therapeutics Inc, Microbiotix Inc, Neoculi Pty Ltd, Nosopharm SAS, Oryn Therapeutics, Peptilogics Inc, Phico Therapeutics Ltd, ReAlta Life Sciences Inc, REMAb Therapeutics SL, Shionogi & Co Ltd, Soligenix Inc, Spero Therapeutics Inc, Summit Therapeutics Plc, Syntiron LLC, VaxNewMO LLC, Vaxxilon AG,

Disease overview, Pipeline trends, market analysis, and other developments

Potential licensing/new business opportunities in Klebsiella pneumoniae Infections pipeline market

Highlights

Global coverage of companies and pipeline agents

2020 Trends, market analysis, and developments

Potential growth opportunities

Comprehensive details of drug candidates

Reasons to Buy

Drive pipeline research and commercial assessment



Assess most promising drug candidates and stay ahead of the competition

Strengthen your pipeline through identifying business expansion and acquisition opportunities

Develop new candidates based on most focused targets and mechanism of actions



Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. KLEBSIELLA PNEUMONIAE INFECTIONS PIPELINE TRENDS AND INSIGHTS

- 2.1 Dominant Phase type of Klebsiella pneumoniae Infections Pipeline, 2020
- 2.2 Most focused Mechanism of Action in Klebsiella pneumoniae Infections Pipeline
- 2.3 Leading type of Route of Administration during 2020
- 2.4 Proportion of New Molecular Entities in Klebsiella pneumoniae Infections pipeline
- 2.5 Active Companies Developing Klebsiella pneumoniae Infections pipeline

3. KLEBSIELLA PNEUMONIAE INFECTIONS DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS

- 3.1 Disease Overview
- 3.2 Types
- 3.3 Symptoms
- 3.4 Approved Treatment Options

4. KLEBSIELLA PNEUMONIAE INFECTIONS PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS

4.1 ABAC Therapeutics SA

AEON Medix Inc

Affinivax Inc

Akthelia Pharmaceuticals Ltd

Appili Therapeutics Inc

Armata Pharmaceuticals Inc

BB200 LLC

Bugworks Research India Pvt Ltd

Celdara Medical LLC

ContraFect Corp

Debiopharm International SA

EnBiotix Inc

F. Hoffmann-La Roche Ltd



Fedora Pharmaceuticals Inc

Forge Therapeutics Inc

Kyorin Pharmaceutical Co Ltd

Melinta Therapeutics Inc

Microbiotix Inc

Neoculi Pty Ltd

Nosopharm SAS

Oryn Therapeutics

Peptilogics Inc

Phico Therapeutics Ltd

ReAlta Life Sciences Inc

REMAb Therapeutics SL

Shionogi & Co Ltd

Soligenix Inc

Spero Therapeutics Inc

Summit Therapeutics Plc

Syntiron LLC

VaxNewMO LLC

Vaxxilon AG

5. KLEBSIELLA PNEUMONIAE INFECTIONS PIPELINE DRUG PROFILES

- 5.1 Current Status of Drug and Vaccine Candidates
- 5.2 Drug Snapshot
 - 5.2.1 Drug
 - 5.2.2 Mechanism of Action
 - 5.2.3 Phase
 - 5.2.4 Co-Developer
 - 5.2.5 Originator
 - 5.2.6 Synonym
 - 5.2.7 Route of Administration
 - 5.2.8 Type of Molecule
 - 5.2.9 Orphan Drug Status
 - 5.2.10 New Molecular Entity
 - 5.2.11 Area
- 5.3 Drug Details
- 5.4 Mechanism of Action
- 5.5 Licensing/Collaboration Agreements
- 5.6 Clinical Trial Details



6. KLEBSIELLA PNEUMONIAE INFECTIONS PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020

7. APPENDIX

- 7.1 About the Publisher
- 7.2 Sources and Research Methodology



I would like to order

Product name: Klebsiella pneumoniae Infections R&D Pipeline Analysis Report, Q4 2020

Product link: https://marketpublishers.com/r/K3727CE2D141EN.html

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/K3727CE2D141EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

riist name.	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature
	- -

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970